182 related articles for article (PubMed ID: 15547071)
1. Lipid lowering drugs prescription and the risk of peripheral neuropathy: an exploratory case-control study using automated databases.
Corrao G; Zambon A; Bertù L; Botteri E; Leoni O; Contiero P
J Epidemiol Community Health; 2004 Dec; 58(12):1047-51. PubMed ID: 15547071
[TBL] [Abstract][Full Text] [Related]
2. Statin use and risk of first-time psoriasis diagnosis.
Brauchli YB; Jick SS; Meier CR
J Am Acad Dermatol; 2011 Jul; 65(1):77-83. PubMed ID: 21529997
[TBL] [Abstract][Full Text] [Related]
3. Lipids, Lipid-Lowering Therapy, and Neuropathy: A Narrative Review.
Pasha R; Azmi S; Ferdousi M; Kalteniece A; Bashir B; Gouni-Berthold I; Malik RA; Soran H
Clin Ther; 2022 Jul; 44(7):1012-1025. PubMed ID: 35810030
[TBL] [Abstract][Full Text] [Related]
4. Statin use and risk of gallstone disease followed by cholecystectomy.
Bodmer M; Brauchli YB; Krähenbühl S; Jick SS; Meier CR
JAMA; 2009 Nov; 302(18):2001-7. PubMed ID: 19903921
[TBL] [Abstract][Full Text] [Related]
5. Use of Lipid-Lowering Drugs and the Risk of Cataract: A Population-Based Nested Case-Control Study.
Bezin J; Mansiaux Y; Noize P; Salvo F; Bégaud B; Pariente A
Clin Pharmacol Ther; 2019 Feb; 105(2):458-465. PubMed ID: 29992538
[TBL] [Abstract][Full Text] [Related]
6. HMG-CoA reductase inhibitors and the risk of fractures.
Meier CR; Schlienger RG; Kraenzlin ME; Schlegel B; Jick H
JAMA; 2000 Jun; 283(24):3205-10. PubMed ID: 10866867
[TBL] [Abstract][Full Text] [Related]
7. Are users of lipid-lowering drugs at increased risk of peripheral neuropathy?
Gaist D; García Rodríguez LA; Huerta C; Hallas J; Sindrup SH
Eur J Clin Pharmacol; 2001 Mar; 56(12):931-3. PubMed ID: 11317483
[TBL] [Abstract][Full Text] [Related]
8. Use of statins and the risk of Parkinson's disease: a retrospective case-control study in the UK.
Becker C; Jick SS; Meier CR
Drug Saf; 2008; 31(5):399-407. PubMed ID: 18422380
[TBL] [Abstract][Full Text] [Related]
9. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs.
Graham DJ; Staffa JA; Shatin D; Andrade SE; Schech SD; La Grenade L; Gurwitz JH; Chan KA; Goodman MJ; Platt R
JAMA; 2004 Dec; 292(21):2585-90. PubMed ID: 15572716
[TBL] [Abstract][Full Text] [Related]
10. Rhabdomyolysis and lipid-lowering drugs.
Tenenbaum A; Fisman EZ; Motro M
JAMA; 2005 Mar; 293(12):1448; author reply 1448-9. PubMed ID: 15784863
[No Abstract] [Full Text] [Related]
11. Use of lipid lowering drugs in patients at very high risk of cardiovascular events: An analysis on nearly 3,000,000 Italian subjects of the ARNO Observatory.
Maggioni AP; Calabria S; Rossi E; Martini N;
Int J Cardiol; 2017 Nov; 246():62-67. PubMed ID: 28298250
[TBL] [Abstract][Full Text] [Related]
12. Association between lipid-lowering agents and severe hyponatremia: a population-based case-control study.
Skov J; Falhammar H; Calissendorff J; Lindh JD; Mannheimer B
Eur J Clin Pharmacol; 2021 May; 77(5):747-755. PubMed ID: 33215235
[TBL] [Abstract][Full Text] [Related]
13. Lipid-lowering drug use and cardiovascular events after myocardial infarction.
Klungel OH; Heckbert SR; de Boer A; Leufkens HG; Sullivan SD; Fishman PA; Veenstra DL; Psaty BM
Ann Pharmacother; 2002 May; 36(5):751-7. PubMed ID: 11978147
[TBL] [Abstract][Full Text] [Related]
14. Are lipid-lowering drugs associated with a risk of cataract? A pharmacovigilance study.
Despas F; Rousseau V; Lafaurie M; De Canecaude C; Durrieu G; Bagheri H; Montastruc F; Montastruc JL
Fundam Clin Pharmacol; 2019 Dec; 33(6):695-702. PubMed ID: 31251421
[TBL] [Abstract][Full Text] [Related]
15. Prevalence of and Factors Associated With the Prescription of Fibrates Among Patients Receiving Lipid-Lowering Drugs in Germany.
Jacob L; Greiner RA; Luedde M; Kostev K
J Cardiovasc Pharmacol; 2021 Dec; 78(6):885-890. PubMed ID: 34654787
[TBL] [Abstract][Full Text] [Related]
16. Statin-associated peripheral neuropathy: review of the literature.
Chong PH; Boskovich A; Stevkovic N; Bartt RE
Pharmacotherapy; 2004 Sep; 24(9):1194-203. PubMed ID: 15460180
[TBL] [Abstract][Full Text] [Related]
17. Differential associations between lipid-lowering drugs, statins and fibrates, and venous thromboembolism: role of drug induced homocysteinemia?
Lacut K; Le Gal G; Abalain JH; Mottier D; Oger E
Thromb Res; 2008; 122(3):314-9. PubMed ID: 18048086
[TBL] [Abstract][Full Text] [Related]
18. Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction.
Hanna IR; Heeke B; Bush H; Brosius L; King-Hageman D; Dudley SC; Beshai JF; Langberg JJ
Heart Rhythm; 2006 Aug; 3(8):881-6. PubMed ID: 16876733
[TBL] [Abstract][Full Text] [Related]
19. Risk of cataract in patients treated with statins.
Schlienger RG; Haefeli WE; Jick H; Meier CR
Arch Intern Med; 2001 Sep; 161(16):2021-6. PubMed ID: 11525705
[TBL] [Abstract][Full Text] [Related]
20. The association between statins exposure and peripheral neuropathy risk: A meta-analysis.
Wang M; Li M; Xie Y
J Clin Pharm Ther; 2021 Aug; 46(4):1046-1054. PubMed ID: 33629752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
